HighTide Therapeutics
Présence
Acquisition, funding and merger involving HighTide Therapeutics.
- HighTide Therapeutics vient d'annoncer une levée de fonds de 107 millions de dollars. (publié le 11 janvier 2023).
Dirigeants
Voir l'organigramme avec ses 10 principaux dirigeants
Biographies les plus recherchées chez HighTide Therapeutics
- Liping Liu, Chief Executive Officer and Chief Science Officer
- Li Yu, Vice General Manager and Head of Human Resources
- Leigh Macconell, Chief Development Officer
Créer une alerte
pour suivre les mouvements de dirigeants chez HighTide Therapeutics.
Biotechnologie
HighTide Therapeutics a 2 284 concurrents dont Lonza (Suisse), Eurofins (Luxembourg) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Transcarent vient d'annoncer une levée de fonds de 126 millions de dollars. (publié le 2 mai 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publié le 2 mai 2024).
- Enlaza Therapeutics vient d'annoncer une levée de fonds de 100 millions de dollars. (publié le 2 mai 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par HighTide Therapeutics
- HighTide-HighTide Therapeutics is Invited to Present at the FII PRIORITY Asia Summit in Hong Kong: Megatrends Shaping Humanity
- HighTide-HighTide Therapeutics Launches Clinical Trial in Hong Kong: Dosing of First Patient in Ongoing Phase 2b Trial of Berberine Ursodeoxycholate (HTD1801) to Treat NASH
- HighTide-HighTide Therapeutics Inc. is Invited to Present at the 7th Edition of the Future Investment Initiative (FII): The New Compass, in Riyadh, Saudi Arabia
- HighTide-HighTide Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Investor Conference
- HighTide-HighTide Therapeutics to Present Data on Improvements in Liver Fat Content and Fibroinflammation Based on MRI Response in Patients with NASH and T2DM treated with Berberine Ursodeoxycholate (HTD1801) at The Liver Meeting® 2023
- HighTide-HighTide is Acknowledged by the HK Government as Strategic Enterprise Partner and has been Invited to the OASES Partnership Launch Ceremony
- HighTide-HighTide Therapeutics Presents Data on the Improvement of Liver Fibroinflammation in Patients with NASH and T2DM at EASL Congress 2023
- HighTide-HighTide Therapeutics Announces Phase 2 Study in Type 2 Diabetes (T2DM) Achieves Primary and Important Secondary Endpoints
- HighTide-Chinese Chamber of Commerce Visits HighTide Therapeutics and Successfully Holds a Symposium
- HighTide-Chinese Chamber of Commerce Visits HighTide Therapeutics and Successfully Holds a Symposium
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de HighTide Therapeutics
- HighTide Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- HighTide Therapeutics sur LinkedIn, Twitter & YouTube en 1-click
